Contact Information <\/p>\n
Available for logged-in reporters only <\/p>\n
Newswise San Francisco, September 14, 2014Patients with stage I and II Hodgkins Disease who receive consolidated radiation therapy (RT) have a higher 10-year survival rate of 84 percent, compared to 76 percent for patients who did not receive RT; and, the data also shows a decrease in utilization of RT, according to research presented today at the American Society for Radiation Oncologys (ASTROs) 56th Annual Meeting. <\/p>\n
Researchers evaluated clinical features and survival outcomes among 41,502 patients diagnosed with stage I and II Hodgkins Disease from 1998 to 2011 from a prospectively collected databasethe National Cancer Data Base (NCDB), which is comprised of cases from 1,500 sites and represents >75 percent of all cancers diagnosed in the U.S. The average patient age was 37 (range: 18 90), with a median follow-up of 7.5 years. The association between RT use, co-variables and outcome were assessed in a multivariate Cox proportional hazards model. Survival was estimated using the Kaplan-Meier method. <\/p>\n
Multi-agent chemotherapy was administered to 96 percent (39,842) of the patients, and 49 percent (20,441) of patients received a median RT dose of 30.6 Gy. The 10-year overall survival of the entire group was 80.8 percent, with patients receiving RT having a statistically significant improved overall survival rate at 10 years, when compared to those not receiving RT (84.4 percent vs. 76.4 percent; p<0.00001). Additionally, the omission of RT was related to higher rates of salvage transplant procedures performed. <\/p>\n
Despite this benefit, the utilization of RT for patients with early-stage Hodgkins Disease decreased at the study sites from 56 percent to 41 percent between 1998 and 2011; and in 88.4 percent of the patients, the physician-reported reason given for not administering RT was that it was not part of the planned initial treatment strategy. The research also indicated that RT use was associated with younger patients (40 years), who are in a higher socioeconomic status, who had access to health insurance, and who received treatment at comprehensive cancer centers (all p<0.0001). <\/p>\n
Multiple prospective, randomized trials have shown a significant improvement in disease control with the addition of RT, however previous trials were limited by low patient numbers and limited follow-up and thus, were unable to demonstrate an overall survival benefit, said lead study author Rahul R. Parikh, MD, a radiation oncologist at Mount Sinai Beth Israel and an Assistant Professor of Radiation Oncology at Icahn School of Medicine at Mount Sinai. This is the largest dataset in this patient population to demonstrate a survival benefit with the addition of RT. Given that the utilization of RT was associated with younger age, insurance status, higher socioeconomic status, and treatment at comprehensive cancer centers, we have highlighted ongoing disparities in Hodgkins Disease treatment and it is important that we recognize these findings as potential barriers to care. Given the survival benefit demonstrated in this study, radiotherapy should be included in the combined modality approach of multi-agent chemotherapy followed by consolidation RT in order to maintain high overall survival rates for this curable disease. <\/p>\n
The abstract, Early-Stage Hodgkin's Disease: The Utilization of Radiation Therapy and Its Impact on Overall Survival, will be presented in detail during a scientific session at ASTROs 56th Annual Meeting at 3:15 p.m. Pacific time on Sunday, September 14, 2014. To speak with Dr. Parikh, please call Michelle Kirkwood on September 14 17, 2014, in the ASTRO Press Office at the Moscone Center in San Francisco at 415-978-3503 or 415-978-3504, or email michellek@astro.org<\/a>. <\/p>\n ASTROs 56th Annual Meeting, to be held at the Moscone Center in San Francisco, September 14-17, 2014, is the nations premier scientific meeting in radiation oncology. The 2014 Annual Meeting is expected to attract more than 11,000 attendees including oncologists from all disciplines, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants, practice administrators, industry representatives and other health care professionals from around the world. Led by ASTRO President Bruce G. Haffty, MD, FASTRO, a radiation oncologist specializing in breast cancer, the theme of the 2014 Meeting is Targeting Cancer: Technology and Biology, and the Presidential Symposium, Local-regional Management of Breast Cancer: A Changing Paradigm, will feature Jay R. Harris, MD, FASTRO, and Thomas A. Buchholz, MD, FASTRO, to highlight recent practice-changing, landmark studies and current developments in the local-regional management of breast cancer. ASTROs four-day scientific meeting includes presentation of up to four plenary papers, 360 oral presentations, 1,862 posters and 144 digital posters in more than 50 educational sessions and scientific panels for 20 disease-site tracks. Three keynote speakers will address a range of topics including oncologic imaging, biology and targeting in oncology, and human error and safety concerns: Hedvig Hricak, MD, PhD, Chair of the Department of Radiology and the Carroll and Milton Petrie Chair at Memorial Sloan Kettering Cancer Center; Frank McCormick, PhD, FRS, DSc (hon), Professor Emeritus and the David A. Wood Distinguished Professor of Tumor Biology and Cancer Research of the University of California at San Francisco Helen Diller Family Comprehensive Cancer Center; and Sidney Dekker, PhD, MA, MSc, Professor and Director of the Safety Science Innovation Lab at Griffith University, Brisbane, Australia. <\/p>\n ABOUT ASTRO ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology Biology Physics (www.redjournal.org) and Practical Radiation Oncology (www.practicalradonc.org); developed and maintains an extensive patient website, http:\/\/www.rtanswers.org<\/a>; and created the Radiation Oncology Institute (www.roinstitute.org), a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http:\/\/www.astro.org<\/a>. ### <\/p>\n <\/p>\n Read more: <\/p>\n Improved Survival Shown in Early-Stage Hodgkin's Disease Patients Who Receive Radiation Therapy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Contact Information Available for logged-in reporters only Newswise San Francisco, September 14, 2014Patients with stage I and II Hodgkins Disease who receive consolidated radiation therapy (RT) have a higher 10-year survival rate of 84 percent, compared to 76 percent for patients who did not receive RT; and, the data also shows a decrease in utilization of RT, according to research presented today at the American Society for Radiation Oncologys (ASTROs) 56th Annual Meeting. Researchers evaluated clinical features and survival outcomes among 41,502 patients diagnosed with stage I and II Hodgkins Disease from 1998 to 2011 from a prospectively collected databasethe National Cancer Data Base (NCDB), which is comprised of cases from 1,500 sites and represents > 75 percent of all cancers diagnosed in the U.S. The average patient age was 37 (range: 18 90), with a median follow-up of 7.5 years Continue reading